Загрузка...
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
INTRODUCTION: Data from the SINGLE trial demonstrated that 88% of treatment-naive HIV-1 patients treated with dolutegravir and abacavir/lamivudine (DTG+ABC/3TC) achieved viral suppression at 48 weeks compared with 81% of patients treated with efavirenz/tenofovir disoproxil fumarate/emtricitabine (EF...
Сохранить в:
| Опубликовано в: : | J Int AIDS Soc |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
International AIDS Society
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4224816/ https://ncbi.nlm.nih.gov/pubmed/25394109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19605 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|